grant
PROJECT 1 – STRUCTURAL BIOLOGY OF DNA DEAMINASES IN CANCER
Organization UNIVERSITY OF TEXAS HLTH SCIENCE CENTERLocation SAN ANTONIO, UNITED STATESPosted 9 Aug 2019Deadline 31 Aug 2030
NIHUS FederalResearch GrantFY2025Active SitesAddressAffinityAnimal ModelAnimal Models and Related StudiesAssayBindingBioassayBiochemicalBiologicalBiological AgentBiological AssayBiological ProductsBiological TestingBody TissuesBurkitt HerpesvirusBurkitt Lymphoma VirusCancer TreatmentCancersCell BodyCell modelCellsCellular modelChemicalsComplementComplement ProteinsComplexComputer ModelsComputerized ModelsCytosineDNADNA mutationDeaminaseDeaminationDeoxyribonucleic AcidDetectionDevelopmentDiseaseDisorderDrug resistanceDrugsEB virusEBVEnzyme GeneEnzymesEpstein Barr VirusEvolutionFamilyFutureGenetic ChangeGenetic defectGenetic mutationGenetics-MutagenesisGenome InstabilityGenomic DNAGenomic InstabilityGenomicsGoalsHHV-4HHV4HerpesviridaeHerpesvirusesHigh Throughput AssayHumanHuman Herpesvirus 4ImmunohistochemistryImmunohistochemistry Cell/TissueImmunohistochemistry Staining MethodInfectious Mononucleosis VirusLarge Subunit Ribonucleotide ReductaseLengthLigandsM1 Subunit Ribonucleotide ReductaseMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMediatingMedicationMedicinal ChemistryMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorModern ManMolecular ConfigurationMolecular ConformationMolecular InteractionMolecular StereochemistryMutagenesisMutagenesis Molecular BiologyMutateMutationN-terminalNH2-terminalNeoplasm MetastasisNormal CellNucleic AcidsOligoOligonucleotidesOutcomePeptidesPharmaceutic ChemistryPharmaceutical ChemistryPharmaceutical PreparationsPositionPositioning AttributeProteinsR1 GeneR1 Subunit Gene Ribonucleotide ReductaseR1 proteinRRM1RRM1 geneReagentResistanceResolutionRibonucleotide ReductaseRibonucleotide Reductase R1 SubunitSecondary NeoplasmSecondary TumorShapesSingle-Stranded DNASourceStructureStructure-Activity RelationshipTechniquesTechnologyTestingTimeTissuesTumor CellTumor PromotionUracilVHHVHH antibodyViralVirus InhibitorsWorkanalogantagonismantagonistanti-cancer therapybiologicbiologicsbiopharmaceuticalbiophysical approachesbiophysical methodologybiophysical methodsbiophysical techniquesbiotherapeutic agentcamelid antibodycamelid based antibodycamelid derived antibodycamelid derived fragmentcamelid heavy chain only Abscamelid immunoglobulincamelid single chain antibodycamelid variable heavy chaincancer metastasiscancer therapycancer-directed therapychemical structure functioncomplementationcomputational modelingcomputational modelscomputer based modelscomputerized modelingconformationconformationalconformational stateconformationallyconformationsdesigndesigningdevelop therapydevelopmentaldrug resistantdrug-like chemicaldrug-like compounddrug-like moleculedrug/agentgDNAgenome mutationherpes virushigh throughput screeninginhibitorinsightintervention developmentmalignancymodel of animalnano engineeringnano-molarnanobodiesnanobodynanoengineeringnanomolarneoplasm/cancerneoplastic cellnoveloligospreferencepreventpreventingprogramsresistance to Drugresistance to therapyresistantresistant to Drugresistant to therapyresolutionssdAbsingle domain antibodiessmall molecular inhibitorsmall moleculesmall molecule inhibitorssDNAstemstructural biologystructure function relationshiptargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic resistancetherapy developmenttherapy resistanttreatment developmenttreatment resistancetumortumor cell metastasisvariable heavy chain antibodyviral genomicsviral inhibitorvirus genomics
Description preview
PROJECT 1 – STRUCTURAL BIOLOGY OF DNA DEAMINASES IN CANCER
ABSTRACT
The human APOBEC3 (A3) family of deaminases catalyze the conversion of cytosine to uracil in single-
stranded DNA to elicit mutations and genome instability, which in turn promote tumor evolution and the
development of therapy resistance and metastatic disease. However, despite…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click